Human medicines European public assessment report (EPAR): Opuviz, aflibercept, Date of authorisation: 13/11/2024, Revision: 3, Status: Authorised

Deadlines for submission of applications for orphan medicinal product designation to the EMA and corresponding COMP timetable for valid applications 2026-2027

EMEA-002036-PIP01-16

Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Zercepac, trastuzumab, Date of authorisation: 27/07/2020, Revision: 14, Status: Authorised

Fosmetpantotenate : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Tagrisso, osimertinib, Date of authorisation: 01/02/2016, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Ziagen, abacavir, Date of authorisation: 08/07/1999, Revision: 50, Status: Authorised

Human medicines European public assessment report (EPAR): Trizivir, abacavir,lamivudine,zidovudine, Date of authorisation: 27/12/2000, Revision: 44, Status: Authorised